
Pulmonx (LUNG) Stock Forecast & Price Target
Pulmonx (LUNG) Analyst Ratings
Bulls say
Pulmonx Corp reported total revenue of $83.8 million for the full year 2024, marking a 22% increase from the previous year, driven by a 23% rise in domestic sales and a 20% growth in international revenue. The company also achieved record Q4 revenue of $23.8 million, which is a 23% increase year-over-year, indicating robust market performance and demand for its innovative medical solutions. Furthermore, the expansion of reimbursement coverage and advancements in patient selection technologies are expected to enhance adoption rates of its products, supporting a positive outlook for sustained revenue growth and market penetration.
Bears say
Pulmonx Corp's gross profit for the latest quarter stood at $17.6 million, reflecting a slight decline in gross margin to 74%, which may indicate challenges in maintaining profitability. A concerning financial trend is observed as the company's cash reserves decreased to $101.5 million from $107.8 million within a three-month span, raising questions about liquidity and operational sustainability. The company operates in a niche market with significant capital volatility, and while it addresses a high unmet medical need, this may not sufficiently counterbalance the financial risks posed by its declining financial metrics and reliance on a limited product range.
This aggregate rating is based on analysts' research of Pulmonx and is not a guaranteed prediction by Public.com or investment advice.
Pulmonx (LUNG) Analyst Forecast & Price Prediction
Start investing in Pulmonx (LUNG)
Order type
Buy in
Order amount
Est. shares
0 shares